Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:15:56 EDT Thu 31 Oct 2024
Enter Symbol
or Name
USA
CA



Q:BPTH - BIO-PATH HOLDINGS INC - http://www.biopathholdings.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BPTH - Q9.90.8006·0.999.00.9055-0.0752-7.7147.21014740.95  0.9699  0.9014.424  0.84619:48:21Oct 1015 min RT 2¢

Recent Trades - Last 10 of 474
Time ETExPriceChangeVolume
19:48:21Q1.00990.0292100
19:33:46Q0.8799-0.1008100
19:32:32Q0.90-0.0807100
19:32:22Q0.90-0.0807500
19:32:22Q0.90-0.080725
19:24:17Q0.9299-0.050890
16:00:03Q0.9055-0.0752142
16:00:03Q0.9055-0.075217
16:00:03Q0.9055-0.075217
16:00:03Q0.9055-0.075215

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-10-10 17:24U:BPTHNews ReleaseBio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
2024-10-08 20:00U:BPTHNews ReleaseBio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
2024-10-08 07:00U:BPTHNews ReleaseBio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
2024-09-16 07:00U:BPTHNews ReleaseBio-Path Holdings Announces Publication in Biomedicines
2024-09-04 17:49U:BPTHNews ReleaseStonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
2024-09-03 07:00U:BPTHNews ReleaseBio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
2024-08-21 07:00U:BPTHNews ReleaseBio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A's Compelling Potential as Treatment for Advanced Solid Tumors
2024-08-15 07:00U:BPTHNews ReleaseBio-Path Holdings Reports Second Quarter 2024 Financial Results
2024-08-08 07:00U:BPTHNews ReleaseBio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
2024-07-08 07:00U:BPTHNews ReleaseBio-Path Holdings Provides Clinical Update and Expansion Plans
2024-06-17 09:45U:BPTHNews ReleaseAcute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
2024-06-14 07:00U:BPTHNews ReleaseBio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
2024-06-05 17:47U:BPTHNews ReleaseBio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
2024-06-04 16:56U:BPTHNews ReleaseStonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
2024-06-04 08:00U:BPTHNews ReleaseBio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
2024-06-03 07:00U:BPTHNews ReleaseBio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
2024-05-24 07:00U:BPTHNews ReleaseBio-Path Holdings to Present Data at 2024 European Hematology Association Congress
2024-05-23 17:00U:BPTHNews ReleaseBio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
2024-05-15 07:00U:BPTHNews ReleaseBio-Path Holdings Reports First Quarter 2024 Financial Results